Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum

CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly's move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate.

Seeking Alpha • 3 hours ago

Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy

Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company's psychological support approach from psychotherapy, Jefferies analysts have highlighted. In a note reviewing a post-hoc analysis of Compass Pathways (NASDAQ:CMPS)' completed Phase II open-label trial of COMP360 in post-traumatic stress disorder (PTSD), Jefferies wrote that the study provided further detail on how the company's treatment model separates monitoring and support during dosing sessions from traditional talk therapy.

Proactive Investors • Jul 17, 2026

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment a.

Business Wire • Jul 16, 2026

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.

Proactive Investors • Jul 13, 2026

Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up

Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.

MarketBeat • Jul 10, 2026

Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission

Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission

Seeking Alpha • Jul 8, 2026

Why Psychedelics-Tied Compass Pathways Isn't Getting High

Compass Pathways stock crumbled Tuesday despite seemingly positive test results for its psychedelic drug in treatment-resistant depression.

Investors Business Daily • Jul 7, 2026

Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline

Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for treatment-resistant depression (TRD).

Benzinga • Jul 7, 2026

COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

Seeking Alpha • Jul 7, 2026

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360's rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported resul.

Business Wire • Jul 7, 2026